

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

OVID THERAPEUTICS, INC.,
Petitioner

v.

MARINUS PHARMACEUTICALS, INC.,
Patent Owner

Case IPR2024-00726
Patent 11,110,100

DECLARATION OF ANNE KOCH BALAND

I, ANNE KOCH BALAND, declare as follows:

1. My name is Anne Koch Baland. I am over the age of 21, and I have personal knowledge of the facts contained herein unless otherwise indicated. I am a Document Delivery Analyst in the library department of Fish & Richardson P.C. (hereafter, "FR Library").

2. I earned a Master of Library Science (MLIS) from Dominican University in 2007. I have over 15 years of experience in the library/information science field.

3. I am experienced in library cataloging. My responsibilities in the FR Library include, among other things, locating various publications in libraries across the country. In the course of my work in the library/information science field, I have regularly searched databases for records of publications. One such database is ProQuest, which is a database search application routinely used by libraries including the FR Library, and in my experience, is a trustworthy and reliable database.

4. I was asked by Marinus's counsel to search for records of the abstract of Exhibit 1008 in this proceeding, titled "Pharmacokinetic and Pharmacodynamic (PK/PD) Relationship of Intravenous Ganaxolone in Refractory Status Epilepticus," with authors "R. Eugene Ramsay," "Aatif M. Hussain," "Christa B. Swisher," "Steven Smith," "Heather Van Heusen," and "Julia Tsai."

5. I searched the ProQuest database for Exhibit 1008's title and author through my ProQuest Dialog account, which is the search engine for the ProQuest database. I purchased the full record available for the resulting entry and produced the ProQuest printout (attached as **Appendix A**). The ProQuest Dialog attributed the source to "Northern Light Life Sciences Conference Abstracts," and provided a URL to that source ("https://discovery.northerlight.com. . ."). I followed the link and printed that record as well (attached as **Appendix B**).

6. I provided both results—the full ProQuest record (**Appendix A**) and the Northern Light record (**Appendix B**) to Marinus's counsel.

I declare under the penalty of perjury that the foregoing is true and correct.

Executed on June 20, 2024.

Anne Koch Baland

Anne Koch Baland

APPENDIX A

Dialog has updated the password policy. **Please ensure you follow the password security rules and change your password if needed.** Once on the search page click [here](#) to update your password.



ProSheets

⚙ Anne ▾

? Help ▾

Workspace ▾

Basic Search

Advanced

Command Line

Find Similar

Look Up Citation

2 Recent searches

0 Selected items

Citation/Abstract

[Back to results](#)

Document 1 of 1

Pharmacokinetic And Pharmacodynamic (PK/PD) Relationship of Intravenous Ganaxolone In Refractory Status Epilepticus

Ramsay, R Eugene; Hussain, Aatif M; Swisher, Christa B; Smith, Steven; Heather Van Heusen; et al. **American Epilepsy Society Annual Meeting 2019** (Dec 6, 2019)

Pricing

Highlighting: Off | Single | Multi

Abstract (summary) [Translate \[unavailable for this document\]](#)

Rapid and maintained seizure cessation is paramount in patients with RSE in order to prevent progression to 3rd line IV anesthetics which may lead to worse clinical outcomes and increased economic burden. IV GNX demonstrated immediate seizure cessation within several minutes upon drug administration as documented on EEG in all patients dosed. The durability of pharmacological response appears to correlate with GNX exposure and ability to maintain target plasma drug levels for an adequate amount of time. These data demonstrate the potential of a new RSE treatment option and support further clinical evaluation in a larger, randomized-controlled Ph3 study. Funding: This ...Copyright © 2023, Northern Light Group, LLC. All Rights Reserved.

Indexing (details)

Cite

Subject	Clinical trial: Phase II Disease: Seizures; Status Epilepticus; Epilepsy Mechanism of action: Anesthetics
Substance	Generic drug: Ganaxolone; Phenytoin; Lacosamide; Levetiracetam; Valproate; Fosphenytoin
Title	Pharmacokinetic And Pharmacodynamic (PK/PD) Relationship of Intravenous Ganaxolone In Refractory Status Epilepticus
Author	Ramsay, R Eugene ¹ ; Hussain, Aatif M ² ; Swisher, Christa B ² ; Smith, Steven ³ ; Heather Van Heusen ³ ; Tsai, Julia ³ ; Masuoka, Lorianne ³ ; Gasior, Maciej ³ ; Vaitkevicius, Henrikas ⁴ ¹ Ochsner Health System ² Duke University ³ Marinus Pharmaceuticals ⁴ Brigham and Women's Hospital
Conference title	American Epilepsy Society Annual Meeting 2019
Conference start date	2019-12-06
Conference sponsor	American Epilepsy Society (AES)
Conference location	Baltimore, MD
Conference country	US
Language	English
Language of abstract	English
Document type	Conference Abstract
Publication title	American Epilepsy Society Annual Meeting 2019
Publication type	Conference Papers & Proceedings
URL	https://discovery.northernlight.com/document.php?datasource=PHE&docid=PE20200210000000470&context=proquest%40northernlight.com
Publication date	Dec 6, 2019
Source attribution	Northern Light Life Sciences Conference Abstracts, © Publisher specific
Accession number	PE20200210000000470
Document URL	https://dialog.proquest.com/professional/docview/2355560987?accountid=156165
First available	2020-02-16
Updates	2020-02-16 2021-04-21 2021-06-30



APPENDIX B

Northern Light Discovery Portal for Life Sciences Conference Abstracts

Document Details

Pharmacokinetic And Pharmacodynamic (PK/PD) Relationship of Intravenous Ganaxolone In Refractory Status Epilepticus



American Epilepsy Society (AES) - American Epilepsy Society Annual Meeting 2019 12/06/2019

Original Abstract Link: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/2421131No longer available? [Find it on Google.](#)

Conference: American Epilepsy Society Annual Meeting 2019

Sponsor: American Epilepsy Society (AES)

Conference Opening Date: 06-Dec-2019

Conference Ending Date: 10-Dec-2019

Location: Baltimore, MD, US

Document Type: Abstract

Summary: Rapid and maintained seizure cessation is paramount in patients with RSE in order to prevent progression to 3rd line IV anesthetics which may lead to worse clinical outcomes and increased economic burden. IV GNX demonstrated immediate seizure cessation within several minutes upon drug administration as documented on EEG in all patients dosed. The durability of pharmacological response appears to correlate with GNX exposure and ability to maintain target plasma drug levels for an adequate amount of time. These data demonstrate the potential of a new RSE treatment option and support further clinical evaluation in a larger, randomized-controlled Ph3 study. Funding: This ...

Authors: R Eugene Ramsay - Ochsner Health System
 Aatif M Hussain - Duke University
 Christa B Swisher - Duke University
 Steven Smith - Marinus Pharmaceuticals
 Heather Van Heusen - Marinus Pharmaceuticals
 Julia Tsai - Marinus Pharmaceuticals
 Lorianne Masuoka - Marinus Pharmaceuticals
 Maciej Gasior - Marinus Pharmaceuticals
 Henrikas Vaitkevicius - Brigham and Women's Hospital

Abstract/Poster Number: 1.136

Entity Mentions	
CONFERENCES	
American Epilepsy Society Annual Meeting 2019, 2019-12-06 1	
CLINICAL TRIALS	
Phase II 1	
DISEASES	
Seizures 7 Epilepsy 2	Status Epilepticus 3
DRUGS - GENERIC	
Ganaxolone 2 Lacosamide 1 Valproate 1	Phenytoin 1 Levetiracetam 1 Fosphenytoin 1
MECHANISMS OF ACTION	
Anesthetics 4	
RESEARCH SCENARIOS	
Seizures is related to Anesthetics. 6 Levetiracetam and Status Epilepticus and Valproate are related. 2 Fosphenytoin and Lacosamide and Status Epilepticus are related. 2 Fosphenytoin and Status Epilepticus and Valproate are related. 2 Status Epilepticus is related to Phenytoin. 2	Epilepsy is related to Status Epilepticus. 4 Lacosamide and Levetiracetam and Status Epilepticus are related. 2 Status Epilepticus is related to Lacosamide. 2 Fosphenytoin and Phenytoin and Status Epilepticus are related. 2 Status Epilepticus is related to Fosphenytoin. 2